Unlike common nutraceuticals stocked in every health store, CJC-1295 moves through a specialist research supply market that Lāthi residents navigate through international suppliers. What this means for Lāthi researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those verification methods are available to every researcher. A credible CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide walks Lāthi researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Lāthi researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. The combination of community consensus and independent COA review is the gold standard for CJC-1295 sourcing — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Lāthi
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and verify they are within the acceptable range for your research context. Researchers running multi-compound protocols with CJC-1295 should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
